ClinicalTrials.gg

Program

EMP-01

A development code.

Its studies are mostly in Phobia, Social, led by Eli Lilly.

Furthest: phase 2, since Nov 12, 20241 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly10 open or runningphase 2since Nov 12, 2024Nov 12, 2024none ahead
  • Named in Eli Lilly’s own pipeline as R-MDMA, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2024First study: phase 2 study in Phobia, SocialFirst studyNCT06693609 · 70 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06693609Phobia, Social · United Kingdom2CompletedDec 10, 202570

How it is read

Names in the registry

  • “EMP-01”, 1 entry

Codes read as this program: EMP01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.